Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double-blind, Randomized, Placebo Controlled, Multicenter, Phase IV Clinical Trial to Assess the Efficacy and Safety of MUCOLASE Tablet (Streptokinase • Streptodornase) in Patients With Acute Upper Respiratory Infection or Acute Bronchitis

NCT04252963 is registered in ClinicalTrials.gov with Hanmi Pharmaceutical Company Limited as lead sponsor.

NCT NCT04252963
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04252963 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double-blind, Randomized, Placebo Controlled, Multicenter, Phase IV Clinical Trial to Assess the Efficacy and Safety of MUCOLASE Tablet (Streptokinase • Streptodornase) in Patients With Acute Upper Respiratory Infection or Acute Bronchitis
Lead sponsor
Hanmi Pharmaceutical Company Limited
Phase
Phase 4
Overall status
Unknown status
Start date
November 2, 2018
Completion date
May 31, 2021
Enrollment
346 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute bronchitis, acute upper respiratory infection